Dublin, March 27, 2026 (GLOBE NEWSWIRE) — The “Bispecific T-Cell Engagers Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The bispecific T-cell engagers market is witnessing remarkable growth with projections showcasing a rise from $1.6 billion in 2025 to $1.94 billion by 2026, marking a CAGR of 21.3%. This trend is attributed to factors like limited efficacy of conventional cancer therapies, rising incidence of hematologic malignancies, breakthroughs in immune-oncology, and increased oncology research investments. Forecasts anticipate the market could reach $4.18 billion by 2030, sustaining a 21.2% CAGR, driven by technological advancements in antibody engineering, higher healthcare investments, and growing strategic partnerships.
Bispecific T-cell engagers are crucial in the fight against cancer, particularly due to the rising global cancer incidence. The mechanism involves binding to both T cells and tumor cells, harnessing the immune system to target cancer more effectively. Reports indicate a significant increase in cancer cases, from 20 million in 2022, expected to surge by 77% to over 35 million by 2050. This alarming rise emphasizes the growing demand for innovative therapies like bispecific T-cell engagers.
Noteworthy corporate strategies are shaping the landscape, with companies focusing on enhancing techniques like cytolytic synapse formation. For instance, Amgen Inc. introduced IMDELLTRA (tarlatamab-dlle) in May 2024, a pioneering therapy approved by the FDA for extensive-stage small cell lung cancer, offering a novel approach in tumor cell targeting. Additionally, acquisitions such as Merck & Co. Inc.’s acquisition of Harpoon Therapeutics Inc. reflect the industry’s momentum towards expanded oncology treatments.
Leading players in the market include giants like Pfizer, Johnson & Johnson, Amgen, Sanofi, and Regeneron Pharmaceuticals, among others. Geographically, North America emerged as the largest market in 2025, with Asia-Pacific anticipated to be the fastest growing region moving forward.
Report Scope
This report addresses the largest and fastest-growing areas within the bispecific T-cell engagers market, analyzing its correlation with broader economic and demographic trends. Key influences include technological innovations, changing regulatory frameworks, and consumer preference shifts.
The report provides a detailed breakdown of market characteristics, growth, segmentation, and competitive dynamics. It tracks historical and forecast growth by geography, exploring major innovations and product developments that differentiate market offerings.
- The supply chain section offers an end-to-end analysis, highlighting key resources and suppliers.
- Emerging trends like digital transformation and AI-driven innovation are discussed in the strategies section, alongside tips for leveraging these for competitive advantage.
- The regulatory and investment landscape highlights policy influences, investment trends, and funding opportunities.
- Market size analysis projects growth trajectories, considering technological influences and global events such as geopolitical tensions and economic shifts.
- Segmentation provides in-depth insights into market subcategories.
- An exploration of the competitive landscape identifies market shares, key financial transactions, and the leading companies.
- The report evaluates leading firms using a multi-parameter company scoring matrix.
Markets Covered:
- By Product Type: Monoclonal Antibodies, Bispecific Antibodies, Other Products
- By Application: Hematologic Malignancies, Solid Tumors, Other Applications
- By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Main Companies: Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., Amgen Inc., among others.
Geographic Coverage: Major countries include the USA, China, Germany, and Brazil, among others, spanning regions such as Asia-Pacific and North America.
The report includes historic data over the past five years and forecasts for ten years ahead, ensuring a comprehensive understanding of market dynamics. Delivered in Word, PDF, or interactive formats with an Excel dashboard, the data is fully customizable and updated bi-annually, supported by expert consultancy services, providing a robust toolkit for decision-makers in the bispecific T-cell engagers market.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $1.94 Billion |
| Forecasted Market Value (USD) by 2030 | $4.18 Billion |
| Compound Annual Growth Rate | 21.2% |
| Regions Covered | Global |
The companies featured in this Bispecific T-Cell Engagers market report include:
- Pfizer Incorporated
- Johnson & Johnson
- F. Hoffmann-La Roche AG
- AbbVie Incorporated
- Sanofi S.A.
- Amgen Incorporated
- Regeneron Pharmaceuticals Incorporated
- Ipsen S.A.
- Genmab A/S
- Evotec SE
- Akeso Inc.
- Immunocore Holdings Public Limited Company
- MacroGenics Incorporated
- Zymeworks Inc.
- Zenas BioPharma Limited
- Candid Therapeutics Inc.
- BPS Bioscience Inc.
- Alloy Therapeutics Inc.
- AP Biosciences Inc.
- Medigene AG
For more information about this report visit https://www.researchandmarkets.com/r/cfsuj8
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Bispecific T-Cell Engagers Market
